Sanofi (NASDAQ:SNY) Receives Average Rating of "Hold" from Brokerages

Key Points

• Analysts: Shares of Sanofi have a consensus rating of Hold from 14 firms (1 sell, 7 hold, 5 buy, 1 strong buy) with an average 1-year price target of $61.50.
• Stock snapshot: Sanofi opened at $46.72, has a market capitalization of $113.95 billion and a P/E of 12.98, with a one-year range of $43.32–$55.77 and roughly 14.0% institutional ownership.

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have been given a consensus rating of "Hold" by the fourteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $61.50.

Several research analysts have commented on SNY shares. Citigroup assumed coverage on Sanofi in a research note on Tuesday, January 27th. They issued a "neutral" rating for the company. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Sanofi in a report on Monday, December 8th. Bank of America lowered shares of Sanofi from a "buy" rating to a "neutral" rating in a research report on Thursday, February 12th. Weiss Ratings cut shares of Sanofi from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Monday, March 23rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Sanofi in a report on Friday, January 16th.

Institutional Investors Weigh In On Sanofi

Institutional investors and hedge funds have recently made changes to their positions in the business. Flagship Harbor Advisors LLC purchased a new position in Sanofi during the fourth quarter worth about $25,000. Financial Consulate Inc. bought a new stake in shares of Sanofi during the 3rd quarter valued at about $26,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Sanofi during the third quarter worth about $29,000. Palisade Asset Management LLC bought a new position in shares of Sanofi in the third quarter worth approximately $30,000. Finally, First Horizon Corp purchased a new stake in Sanofi in the third quarter valued at approximately $33,000. Hedge funds and other institutional investors own 14.03% of the company's stock.

Sanofi Price Performance

Sanofi stock opened at $46.72 on Tuesday. The firm has a market capitalization of $113.95 billion, a P/E ratio of 12.98, a PEG ratio of 1.16 and a beta of 0.45. Sanofi has a one year low of $43.32 and a one year high of $55.77. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. The business has a fifty day moving average price of $46.32 and a 200-day moving average price of $47.99.

About Sanofi

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.